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PRECLINICAL AND
CLINICAL IMAGING-
Note
Characterizing Blood–Brain Barrier Perturbations after
Exposure to Human Triglyceride-Rich Lipoprotein
Lipolysis Products Using MRI in a Rat Model
Kit Fai Ng,1 Steve Anderson,2 Patrice Mayo,1 Hnin Hnin Aung,1 Jeffrey H. Walton,3 and
John C. Rutledge1*
Purpose: Previous studies indicated hyperlipidemia may be a
risk factor for Alzheimer’s disease, but the contributions of
postprandial triglyceride-rich lipoprotein (TGRL) are not known.
In this study, changes in blood–brain barrier diffusional trans-
port following exposure to human TGRL lipolysis products
were studied using MRI in a rat model.
Methods: Male Sprague-Dawley rats (180–250 g) received an
i.v. injection of lipoprotein lipase (LpL)-hydrolyzed TGRL (n¼8,
plasma concentration  150 mg human TGRL/dL). Controls
received i.v. injection of either saline (n¼6) or LpL only (n¼6).
The 1H longitudinal relaxation rate R1¼1/T1 was measured over
18 min using a rapid-acquired refocus-echo (RARE) sequence
after each of three injections of the contrast agent Gd-DTPA. Pat-
lak plots were generated for each pixel yielding blood-to-brain
transfer coefficients, Ki, chosen for best fit to impermeable, uni-
directional influx or bi-directional flux models using the F-test.
Results: Analysis from a 2-mm slice, 2-mm rostral to the
bregma showed a 275% increase of mean Ki during the first
20 min after infusion of human TGRL lipolysis product that dif-
fered significantly compared with saline and LpL controls. This
difference disappeared by 40 min mark.
Conclusion: These results suggest human TGRL lipolysis prod-
ucts can lead to a transient increase in rat BBB permeability.
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INTRODUCTION
Alzheimer’s disease (AD) is a progressive neurodegenera-
tive disease characterized by irreversible memory loss,
deposition of amyloid plaques, neurofibrillary tangles,
and brain atrophy (1). In 2012 alone, one in eight Ameri-
cans over 65 was afflicted with AD, i.e., 5.4 million
patients, or approximately 2% of the U.S. population (2).
AD and cardiovascular diseases (CVD) share very similar
risk factors, including hypertension, apolipoprotein-E4
genotype and type 2 diabetes (3). Furthermore, lipid pro-
files of AD patients are also similar to those who are at risk
of CVD, and in particular high plasma triglyceride is corre-
lated with vascular dementia and AD (4–6). Yet clinical
trials aimed to lower triglyceride content using fibrate
drugs have had mixed results (7,8). There is also increased
recognition that blood–brain barrier (BBB) dysfunction
could be a contributing factor (6,9–11). Simply put, there
is still no consensus on the etiology of AD.
While numerous studies have demonstrated elevated
fasting triglyceride concentration is a risk factor for AD,
the contribution of postprandial hypertriglyceridemia to
AD is unknown. Dietary lipids are absorbed in the intes-
tine and secreted into the circulation as chylomicrons
within 3 to 4 h after ingesting a moderate to high fat meal
(12). Alternately, endogenously synthesized triglycerides
are transported by very-low density lipoproteins (VLDL)
that are produced in the liver. Together chylomicrons and
VLDL are classified as triglyceride-rich lipoproteins
(TGRL). Their compositions vary within a range of 50–
90% triglyceride content and sizes vary between 25 and
1000 nm. Circulating TGRLs are hydrolyzed by
endothelial-bound lipoprotein lipase (LpL) that have been
found on brain microvessels (13). Hydrolyzing TGRLs
releases a conglomerate of free fatty acids and phospholi-
pids known as lipolysis products. At high physiological to
pathophysiological concentrations, these lipolysis prod-
ucts are harmful to human aortic endothelial cells (HAEC)
and pathophysiological effects include rearrangement of
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junction proteins that lead to increased endothelial per-
meability, inflammation and apoptosis (14). Although
HAEC and cerebrovascular cells are different, it is likely
they can both be injured by lipolysis products. However, it
is unknown if TGRL lipolysis products cause permeability
changes of the BBB, even if transiently.
To test this hypothesis, we used MR contrast agent
(MRCA)-assisted MRI as used extensively in assessing BBB
injury after stroke both clinically and experimentally (15,16).
MRCA-MRI has the advantage of achieving relatively high
resolution and being relatively noninvasive, allowing a
subject to be monitored over time. Here in this study,
MRCA-MRI was used to measure the blood-to-brain
influx coefficient Ki as a measure of BBB integrity in healthy
Sprague-Dawley rats after injection of saline, LpL, or prelipo-
lyzed human TGRL (final blood concentration of 150 mg/dL
TGRL, hereafter designated 150TL).
METHODS
Preparation of Human Triglyceride-Rich Lipoprotein
Lipolysis Products
As approved by the UC Davis Institutional Review Board,
plasma samples were collected from healthy volunteers
3.5 h after consuming a high fat meal. TGRL from these
plasma samples was isolated by ultracentrifugation at
40,000 rpm at 14C for 18 h with a density gradient solu-
tion (r¼ 1.0063 g/mL), followed by dialysis against a 0.9%
NaClþ 0.01% ethylenediaminetetraacetic acid solution
overnight. Triglyceride content was assessed using an
enzymatic assay kit (Sigma, St. Louis, MO). Before animal
infusion, TGRL was concentrated with Amicon 3000
MWCO centrifugal filters (Millipore, Billerica, MA) before
incubation for at least 30 min with LpL added at 2 U/mL
per 150 mg/dL.
Animal Preparation
Twenty Sprague-Dawley rats (Charles River Laboratories,
Wilmington, MA) weighing 180–250 g were studied as
approved by the Animal Use and Care Committee at the
University of California, Davis. Animals were anesthetized
with sodium pentobarbital (60 mg/kg body weight, i.p)
and surgical plane anesthesia maintained with a quarter
dose (15 mg/kg body weight, i.p) every 30 to 45 min there-
after. Body temperature was maintained by an electric
heating pad during surgery and a water heating pad (Gay-
mar Inc., Orchard Park, NY) during MRI as described
previously (17). The left femoral vein was cannulated with
PE-50 polyethylene tubing for infusion of saline, LpL or
150TL, and gadopentetate dimeglumine (Magnevist; Bayer
Healthcare Pharmaceuticals, Wayne, NJ).
Blood Chemistry
Blood samples from a subset of animals were drawn
from the venous cannula at the conclusion of MRI data
acquisition and analyzed for electrolytes, pH, PCO2, PO2,
hemoglobin, and hematocrit using the i-STAT device
(Abbott Laboratories, Abbott Park, IL).
MRI Analysis of Brain Permeability Changes
MRI data were collected using a 7 Tesla (T) Bruker Biospec
MRS/MRI system (Bruker Biospin MRI, Inc., Billerica, MA).
Anesthetized rats were placed supine on a custom made
Plexiglas stage. The stage and rat were then placed into a 72-
mm radio frequency probe inside the 7T magnet centering
2 mm rostral to the bregma [slice 44 in the Scalable Brain
Atlas (18)]. A previously described rapid-acquisition refo-
cused-echo (RARE) sequence was used to create T1 maps
(19). In brief, images were captured using a 64-mm field-of-
view with a matrix of 128  128 pixels with a 2-mm thick-
ness in 1.8 min. The imaging parameters were echo time
(TE)¼ 10.26 ms; repetition time (TR) array¼ 168.4, 500.2,
927.1, 1525.9, 2538, and 7500 ms; and RARE factor¼16.
After a baseline T1 map was acquired, a 0.5 mL/kg bolus of
Magnevist (250 mmol/kg) was injected i.v. over approxi-
mately 4 s. The time course of contrast created by each bolus
was then followed to acquire a total of 10 T1 maps over a
period of 18 min for each of 3 Magnevist injections. The
regions of interest (ROIs) were two symmetrical ROIs, one
from each hemisphere, chosen to maximize the number of
pixels sampled while excluding pixels in the median emi-
nence or outside the brain in the manner described by
Nagaraja et al (20). A single pixel sampling the superior sag-
ittal sinus (SSS) was selected to follow the change in R1¼ 1/
T1 for the arterial input function of each Magnevist injection
as previously described (19,21). Matlab (MathWorks, Natick,
MA) was used to convert T1 maps to R1 maps and generate
Patlak plots for each pixel to calculate the blood to brain
transfer rate coefficient, Ki (min
1), constrained using F-
tests to select the best fit between impermeable, uni-
directional influx and bi-directional flux models (21,22).
Statistical Analysis
Unless otherwise stated, data are reported as mean6SEM.
Analysis of variance for repeated measures was used to
test for differences between treatments using the criterion
of P< 0.05. When differences between treatments were
found, the Student-Newman-Keuls (SNK) posthoc test for
multiple comparisons was used to determine which and
when treatments were different.
RESULTS
Physiological Data
Venous blood samples from a subset of rats (n¼ 9) were
analyzed and summarized in Table 1. Mean PCO2 was
57.516 5.23 mmHg and there were no significant differ-
ences between treatment groups. Mean PO2 was
39.296 3.66 mmHg. Because physiological venous PO2 is
near 40 mmHg and PCO2 is between 40 and 50 mmHg,
the rats were slightly hypoxic and hypercapnic.
Ki Was Significantly Increased in Rats Treated with TGRL
Lipolysis Products
Ki was calculated on a pixel-by-pixel basis and then
averaged over two ROIs selected symmetrically about the
midline from each hemisphere away from the median
eminence and ventricles. Representative images of Ki for
an animal injected with 150TL are shown in Figure 1.
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(Data were collected from rats lying supine but the
images were inverted for illustration purposes.) Repre-
sentative ROIs are highlighted by green border and the
SSS used for the arterial input function is indicated by
the white arrow. Mean Ki for each treatment group was
plotted against time (Fig. 2) demonstrating Ki for 150TL
increased 275% from baseline control. Analysis of var-
iance (ANOVA) for repeated measures showed mean Ki
for 150TL was significantly greater than LPL and saline
when results for all three time points were included.
The SNK posthoc analysis showed Ki for 150TL was sig-
nificantly greater than for LpL alone for the 0- to 20-min
interval but SNK showed no significant difference
between treatments for the 20- to 40-min interval. Stand-
ard t-tests for the 0- to 20-min interval comparing 150TL
with saline and LpL infusions gave P¼ 0.024 and 0.035,
respectively. Finally, in an effort to quantify the number
of leaky sites, for each animal we counted the number of
pixels with Ki 2 SDs greater than the mean of its own
control Ki. Consistent with findings described above,
ANOVA for repeated measures showed there was an
increased number of high Ki pixels in the 150TL group
compared with both LpL alone as well as for saline.
Standard ANOVA followed by SNK analysis showed the
significant difference between treatments occurred for
the 0- to 20-min interval (Fig. 3). Although SNK analysis
did not show significant differences between individual
treatments at any particular time, standard t-tests com-
paring 150TL with saline and LpL infusions had P-val-
ues of 0.052 and 0.026, respectively for the 0- to 20-min
interval and 0.081 and 0.043, respectively, for the 20- to
40-min interval.
DISCUSSION
The neurovascular unit remains a central focus of AD
research. It is composed of such components as endothelial
cells, basement membrane, astrocytes, pericytes, and neu-
rons. The endothelial cells normally maintain a barrier to
segregate blood-borne substances from the brain extracellu-
lar fluid, i.e., the BBB, while regulating the entry of endo-
crine factors, immune cells and cytokines, and the secretion
of cytokines (23,24). BBB permeability can be increased by
perturbations such as hypoxia, ischemia/reperfusion,
inflammation, and brain tumors and assessing these
changes is important for understanding the etiology of cere-
brovascular diseases (25,26).
AD is one such disease in which BBB integrity seems to
play an important role. In the ADmouse model Tg2576 BBB
integrity was compromised as early as 4 months in some
areas of the cerebral cortex (27). In humans, disturbances in
the cerebral-spinal fluid albumin index (a measure of BBB
integrity) are positively correlated with AD progression (28).
Damage to the BBB in the hippocampus is also correlated
with AD in the early stage (29). In an analogous system, loss
of endothelial integrity in the systemic circulation is also
correlated with atherosclerosis (30). In addition, risk factors
for CVD also coincide with AD. These shared risk factors
include hypertension, high LDL cholesterol, low HDL cho-
lesterol, diabetes, and high triglycerides (3,5,31). However,
evidence also exists for no overlap of these risk factors (4)
and clinical trials lowering high plasma triglyceride with
fibrate drugs have yieldedmixed results (7,8).
FIG. 1. Representative images of rat brain treated with 150TL at different time points. The color bar below the images shows changes
in blood–brain barrier transfer coefficient Ki varying from 0 to 0.03 min
21. Pixels with Ki>0.03 min
21 are assigned the same color as
Ki¼0.03 min21. For each map, representative ROIs in each hemisphere are highlighted by green border and the white arrow points to
the SSS. Rats were lying supine during data collection and images were inverted for illustration purposes. Please see text for further
detail.
Table 1
Physiologic Datay
Na (mmol/L) 140.786 1.33
K (mmol/L) 4.7160.29
TCO2 (mmol/L) 33.0061.66
Ca (mmol/L) 1.3060.05
Hematocrit (%PCV) 37.4460.60
Hemoglobin (g/DL) 12.7460.21
pH 7.3560.02
PCO2 (mmHg) 57.5165.23
PO2 (mmHg) 39.2963.66
HCO3 (mmol/L) 31.1461.50
aVenous blood samples from a subset of animals were analyzed
using i-STAT (N¼9).
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Some of these mixed results could be due to the differ-
ence between triglyceride and triglyceride lipolysis prod-
ucts. Vascular lipoprotein lipase hydrolyzes TGRLs and
releases neutral and oxidized free fatty acids. We previ-
ously demonstrated that these lipolysis products of
TGRLs caused extensive rearrangement of junctional pro-
teins such as ZO-1 and occludins in HAEC (14) and
increased reactive oxygen species production (32). In
contrast, un-hydrolyzed TGRL did not induce similar
effects, suggesting that it is the released contents from
TGRL hydrolysis and not the plasma concentration of tri-
glyceride that is deleterious to the vasculature. There-
fore, prelipolyzed triglyceride was used to study the
acute effect on the BBB in this study.
Our study here shows that after normal rats were fed
regular chow, infusing human lipolysis products to
obtain a blood level of 150 mg/dL TGRL transiently
increased the blood-to-brain transfer coefficient (Ki) for
Gd-DTPA (Fig. 2). That is, the time course of our experi-
ment suggests Ki increased within 20 min after injecting
150TL and then fell toward baseline within 40 min after-
ward. This rise-and-fall trend, however, does not appear
to be true for the mean number of pixels having Ki more
than 2 SDs above control (Fig. 3). While the change is
not statistically significant using the Student-Newman-
Keuls test, the difference in the trends could be due to
variability of the pixels sampled with the MRI.
While the majority of pixels made low to moderately
leaky by the 150TL infusion were no longer significantly
different from those treated with saline or LpL after 40
min, t-test analysis suggests a trend showing the mean
number of very leaky pixels (i.e.,> 2 SD greater than
baseline) is greater 40 min after 150TL treatment
than after LpL infusion. One interpretation of this
result is that lower permeability sites recover while more
leaky sites do not recover within the same time interval.
This, however, remains speculative and requires further
study.
Furthermore, the infusion of human TGRL lipolysis
products is physiologically relevant despite the acute
nature of the infusion. Even though blood TGRL in
humans rises steadily from initial fat assimilation in the
intestine to peak at 3 h after ingesting a particular meal
(12), allometric considerations suggest this is accelerated
in rats. In addition, it is well documented that LpL can
be found within brain microvessels as well as brain and
nervous system (13,33). Therefore incubating TGRL with
lipoprotein lipase (LPL) before injection would likely
accelerate the observed effects of TGRL lipolysis prod-
ucts. As a corollary, injecting TGRL without LpL incuba-
tion would likely just delay the onset of the permeability
changes. Further studies will be required to test this
assertion as well.
While our current study does not tell us the mecha-
nism of the observed blood-to-brain transfer coefficient
changes, it would likely involve the transforming growth
factor-b/SMAD pathway as suggested by previous obser-
vations in HAEC with similar treatments (unpublished
results). Nonetheless certain artifacts could be ruled out.
First, the Patlak model for the blood-to-brain transfer rate
coefficient Ki (as the product of capillary permeability
and surface area per tissue volume) could depend on the
flow rate, as Ewing et al estimated a perfusion rate less
than 50 times Ki could create a flow-limited situation
(21). The reason being that changes in blood flow could
be associated with changes in surface area and/or meas-
ured permeability if contrast agent delivery is flow lim-
ited. Using an MRI sequence to generate perfusion
weighted images from our samples, more than 90% of
our dataset had a cerebral blood flow above this limit
(data not shown).
Furthermore, to the extent that Ki measurements are
flow-limited, this will underestimate Ki. Therefore the
increases we measured in the 150TL group are a
FIG. 2. Mean blood to brain transfer rate coefficients Ki are plot-
ted against time. ROIs are selected from brain hemispheres and
combined to calculate a mean for each animal. Then mean Ki for
all animals in each treatment is plotted at three different time
points representing the time for data acquisition (control, 0–20 min
and 20–40 min). ANOVA for repeated measures showed a signifi-
cant difference (P<0.05) in Ki between animals infused with
150TL (n¼8) and those infused with either saline (n¼6) or with
LpL alone (n¼6). Posthoc analysis showed in particular that a dif-
ference between 150TL and LpL alone occurred at the 0–20 min
time point (*P<0.05).
FIG. 3. Mean number of pixels having a blood to brain transfer
coefficient Ki more than 2 SDs greater than the same animal’s
control plotted against each time point. Using the criteria outlined
by Nagaraja et al (20), pixels are considered to be very leaky if the
Ki is more than 2SDs greater than control. ANOVA for repeated
measures shows animals infused with 150TL have more leaky pix-
els by this criterion compared with those infused with saline or
LpL alone (P<0.05). Standard ANOVA for multiple comparisons
showed the effect of treatment was significant for the 0–20 min
interval (*P<0.05).
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conservative estimate and any possible flow-limitation
will not invalidate the conclusion that 150TL infusion
increases the Ki. Second, even though the experimental
animals were slightly hypoxic and hypercapnic, likely
due to the use of Nembutal that is known to suppress
ventilation without procedural intervention, studies have
shown that only after 3 h of acute and severe hypercap-
nia (PACO2> 65 mmHg), but not after continuous hyper-
capnia, was BBB function disturbed in rabbits (34).
Mean PCO2 in the experimental animals is well below
this level of hypercapnia (Table 1) and no correlation
between venous PCO2 and Ki could be found (data not
shown). Therefore, the observed changes in blood-to-
brain transfer coefficient are not likely due to blood flow
changes in the brain or hypoxia or hypercapnia.
While pinpointing the exact lipolysis product that
caused the observed changes is beyond the scope of this
study, there can be possible candidates. Apart from
transporting lipid, TGRL can also transport amyloid-beta
(Ab). Chylomicrons, a class of TGRL produced in the
intestine to facilitate triglyceride transport from dietary
lipid, are carriers for Ab (35,36). Elevated triglyceride
also preceded Ab deposition in two AD mouse models
(37). Takechi et al hypothesized the increased Ab-
chylomicron load that occurs during chronic high fat
feeding might lead to more intestinally produced Ab
deposition in the brain (38). It is possible that TGRL
lipolysis released this Ab fraction that injured the BBB
and led to the study observations. Further studies will
be needed to distinguish the effects, if any, between
TGRL lipolysis products and Ab in our model.
In conclusion, we have demonstrated in this study
that RARE-MRI measurement of changes in T1 fol-
lowing contrast agent infusion is a useful technique to
monitor the changes of blood–brain barrier function
in vivo following TGRL lipolysis product infusion
and that under the conditions of this study, TGRL
lipolysis products transiently increase the blood-to-brain
transfer coefficient for Gd-DTPA. To our knowledge this
is the first use of this technique to examine this pheno-
menon in vivo. This result provides important insight
into the effects of lipids on BBB permeability and
this technique could be a valuable tool for testing the
efficacy of lipid-modulating drugs in maintaining BBB
function.
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